AnaptysBio, Inc. (ANAB)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$56.80-1.15%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · ANAB
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -40.5% |
| Our one-year growth estimate | diamond | -33.2% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 7.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Elevated risk of a next-quarter earnings miss: this name has erratic recent earnings surprises and has been missing across recent quarters. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
ANAB — earnings miss
Dated 2026-05-12
Results of Operations and Financial Condition. On May 12, 2026, AnaptysBio, Inc. (“AnaptysBio”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Item 2.02, including Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or…
Why it matters: The spin-off could unlock value and clarify AnaptysBio's focus. It’s a key priority.
Supportive ifCompletion of the spin-off with a clear timeline and financial details.
Worry ifThere may be a delay or cancellation of the spin-off announcement.
Why it matters: If healthcare sector revenue growth speeds up, it may help AnaptysBio's performance. This could signal a better environment for biotech companies.
Supportive ifHealthcare sector revenue growth exceeds 10% year over year.
Worry ifHealthcare sector revenue growth remains below 10% year over year.
Why it matters: Positive data from AZUR-4 could enhance the outlook for Jemperli and its royalties.
Supportive ifAnaptysBio shares good data from the AZUR-4 trial in Q4 2026.
Worry ifData from the AZUR-4 trial is not good or unclear.
Why it matters: Changes in sales guidance will change AnaptysBio's royalty expectations. This will impact stock performance.
Watch forGSK raised Jemperli sales guidance to over $2.7 billion. This means stronger future royalties for AnaptysBio.
Also watch forGSK lowered Jemperli sales guidance to below $2.7 billion. This suggests weaker future royalties.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$206 on $10,000 · ±2.1% | How much price usually moves either way. |
| Bad day | $505 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $2,796 loss on $10,000 · 28.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A smaller net loss shows better financial health and more efficient operations.
Supportive ifQ2 2026 net loss reported less than $52.9 million.
Worry ifNet loss increases beyond $52.9 million in Q2 2026.
Why it matters: Completing the repurchase plan signals confidence in the company's value. It may also support share price.
Supportive ifAnaptys finishes the $100 million stock buyback plan.
Worry ifAnaptys suspends or cancels the stock repurchase plan.
Why it matters: Jemperli's strong sales growth helps AnaptysBio expect more royalties. This affects future revenue.
Supportive ifGSK reports Jemperli sales growth above 40% year over year in Q2 2026.
Worry ifGSK reports Jemperli sales growth below 20% year over year in Q2 2026.
Why it matters: Good trial data could improve Jemperli's market potential. It would also help AnaptysBio's royalty outlook.
Watch forPositive data from the AZUR-4 Phase 2 trial for dostarlimab will be out by Q4 2026.
Also watch forNegative data or delays reported from AZUR-4 Phase 2 trial.
Why it matters: Paying off debt would help financial health. It would also support AnaptysBio's royalty plans.
Supportive ifAnnouncement of the paydown of the remaining $325 million non-recourse debt by the end of Q2 2027.
Worry ifFurther delays in debt paydown or no announcement by the end of Q2 2027.
Why it matters: This shows strong sales growth. It also helps management reach their long-term royalty goal.
Supportive ifQ2 Jemperli royalties were over $97.5 million. This shows strong growth.
Worry ifQ2 Jemperli royalties were below $97.5 million. This suggests slower growth.
Why it matters: Doing well would show they care about giving value to shareholders. It would help the stock price.
Supportive ifAnnouncement of stock repurchases totaling at least $25 million by the end of Q3 2026.
Worry ifNo stock repurchases reported by the end of Q3 2026.